Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Ellard

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Investigational New Drugs|March 28, 2014
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancerArun A Azad, Emma K Beardsley, Sebastian J Hotte, et al.
BMJ Open|August 18, 2016
Innovative approach for increasing physical activity among breast cancer survivors: protocol for Project MOVE, a quasi-experimental studyCristina M Caperchione, Catherine M Sabiston, Marianne I Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyJ J Biagi, A M Oza, H I Chalchal, et al.
Translational Behavioral Medicine|July 31, 2018
Utilizing RE-AIM to examine the translational potential of Project MOVE, a novel intervention for increasing physical activity levels in breast cancer survivorsTanya Pullen, Joan L Bottorff, Catherine M Sabiston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi, S L Ellard, S J Hotte, et al.
BMC Cancer|March 29, 2019
A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVECristina M Caperchione, Catherine M Sabiston, Sean Stolp, et al.
The Oncologist|January 15, 2016
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant ChemotherapyGraeme J Koelwyn, Nia C Lewis, Susan L Ellard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Breast Cancer Research and Treatment|November 8, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO studyDiogo Martins-Branco, Marie Kassapian, Véronique Debien, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Investigational New Drugs|March 28, 2014
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancerArun A Azad, Emma K Beardsley, Sebastian J Hotte, et al.
BMJ Open|August 18, 2016
Innovative approach for increasing physical activity among breast cancer survivors: protocol for Project MOVE, a quasi-experimental studyCristina M Caperchione, Catherine M Sabiston, Marianne I Clark, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group StudyJ J Biagi, A M Oza, H I Chalchal, et al.
Translational Behavioral Medicine|July 31, 2018
Utilizing RE-AIM to examine the translational potential of Project MOVE, a novel intervention for increasing physical activity levels in breast cancer survivorsTanya Pullen, Joan L Bottorff, Catherine M Sabiston, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 7, 2007
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancerK N Chi, S L Ellard, S J Hotte, et al.
BMC Cancer|March 29, 2019
A preliminary trial examining a 'real world' approach for increasing physical activity among breast cancer survivors: findings from project MOVECristina M Caperchione, Catherine M Sabiston, Sean Stolp, et al.
The Oncologist|January 15, 2016
Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant ChemotherapyGraeme J Koelwyn, Nia C Lewis, Susan L Ellard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163Susan L Ellard, Mark Clemons, Karen A Gelmon, et al.
Breast Cancer Research : BCR|May 4, 2017
A phase-I study of lapatinib in combination with foretinib, a c-MET, AXL and vascular endothelial growth factor receptor inhibitor, in human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancerStephen K Chia, Susan L Ellard, Mihaela Mates, et al.
Breast Cancer Research and Treatment|November 8, 2023
The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO studyDiogo Martins-Branco, Marie Kassapian, Véronique Debien, et al.
Pageof 4